Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E20.21 EPS (ttm)1.97 Insider Own0.20% Shs Outstand2.51B Perf Week-2.66%
Market Cap99.83B Forward P/E12.87 EPS next Y3.10 Insider Trans0.00% Shs Float2.49B Perf Month-2.35%
Income4.90B PEG2.13 EPS next Q0.65 Inst Own11.00% Short Float0.35% Perf Quarter2.23%
Sales40.30B P/S2.48 EPS this Y42.70% Inst Trans-0.01% Short Ratio3.19 Perf Half Y0.13%
Book/sh2.32 P/B17.18 EPS next Y6.43% ROA6.30% Target Price44.33 Perf Year-1.46%
Cash/sh2.07 P/C19.29 EPS next 5Y9.50% ROE116.40% 52W Range36.41 - 42.36 Perf YTD4.29%
Dividend2.39 P/FCF24.23 EPS past 5Y-7.40% ROI16.00% 52W High-5.93% Beta0.74
Dividend %6.00% Quick Ratio0.50 Sales past 5Y3.10% Gross Margin68.50% 52W Low9.45% ATR0.42
Employees95490 Current Ratio0.80 Sales Q/Q7.30% Oper. Margin17.80% RSI (14)26.09 Volatility1.24% 0.92%
OptionableYes Debt/Eq5.98 EPS Q/Q147.10% Profit Margin11.80% Rel Volume0.98 Prev Close39.98
ShortableYes LT Debt/Eq4.65 EarningsMay 08 BMO Payout83.00% Avg Volume2.73M Price39.85
Recom2.00 SMA20-3.56% SMA50-2.44% SMA200-0.58% Volume2,670,135 Change-0.33%
Mar-08-19Downgrade Shore Capital Buy → Hold
Feb-22-19Downgrade UBS Buy → Neutral
Jan-14-19Downgrade Exane BNP Paribas Outperform → Neutral
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Aug-30-18Downgrade Liberum Buy → Hold
Apr-04-18Upgrade Exane BNP Paribas Neutral → Outperform
Mar-22-18Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-09-18Upgrade Kepler Reduce → Hold
Nov-06-17Downgrade Investec Buy → Hold
Oct-26-17Downgrade BofA/Merrill Buy → Neutral
Sep-08-17Downgrade Morgan Stanley Equal-Weight → Underweight
Jul-05-17Downgrade Citigroup Buy → Neutral
May-26-17Upgrade Berenberg Hold → Buy
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Apr-19-19 10:43AM  GSK cutting employees at its R&D unit in Collegeville American City Business Journals
Apr-18-19 11:29AM  Clovis Focuses on Rubraca Label Expansion, Competition Stiff Zacks
Apr-17-19 02:30PM  COPD space about to have another drug this time from a Morrisville concern American City Business Journals
11:01AM  Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study Zacks
Apr-16-19 11:07AM  Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up Zacks
10:57AM  Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA Zacks
Apr-15-19 09:57AM  Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks
05:28AM  London's FTSE 100 tugged down by miners; IWG lifts midcaps Reuters
Apr-14-19 08:07PM  Top 5 Dividend Stocks in the FTSE for 2018 Investopedia
Apr-12-19 11:08AM  Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group Zacks
10:30AM  Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal Zacks
Apr-11-19 06:20PM  Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon Zacks
Apr-10-19 10:14AM  AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks
Apr-09-19 11:19AM  Dont Give Up on Gilead Stock After GlaxoSmithKline Beat It to a New HIV Drug, Analyst Says
10:59AM  Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth Zacks
08:02AM  Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients Zacks
Apr-08-19 05:25PM  Gilead Files sNDA for Label Expansion of HIV Therapy Descovy Zacks
04:51PM  GSK wins U.S. nod for two-drug HIV combination Reuters
03:56PM  U.S. FDA approves GSK's two-drug HIV treatment Reuters
03:46PM  U.S. FDA approves GSK's two-drug HIV treatment Reuters
10:00AM  3 Top Biotech Stocks to Buy in April Motley Fool
04:26AM  GSK two-drug/one-pill HIV treatment given FDA approval in US Financial Times
Apr-05-19 08:00AM  Health Day Checkup of Medical ETFs: 5 Top Picks Zacks
Apr-04-19 09:39AM  Novartis Resubmits BLA to FDA for Biosimilar of Neulasta Zacks
Apr-03-19 10:22AM  Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks
Apr-02-19 10:18AM  Novartis Gets Approval for Psoriasis Drug Cosentyx in China Zacks
10:04AM  Merck's Keytruda Gets Nod for First-Line Lung Cancer in China Zacks
Apr-01-19 02:31PM  Top Analyst Reports for Chevron, IBM & Medtronic Zacks
08:53AM  3 Big Pharma Stocks to Add to Your Portfolio This April Zacks
Mar-29-19 08:10PM  3 Dividend Stocks That Pay You Better Than Coca-Cola Does Motley Fool
12:45PM  Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga
12:10PM  The Brexit Day That Wasn't Leaves Britain Counting the Cost Bloomberg
Mar-28-19 01:29PM  European shares give up gains as banks weigh amid concerns on growth, Brexit Reuters
09:52AM  One Key Strategy to Build Your Ultimate Retirement Portfolio InvestorPlace
Mar-27-19 02:47PM  5 Cancer-Fighting Stocks to Boost Portfolio Gains Zacks
09:33AM  Were Hedge Funds Right About Deserting GlaxoSmithKline plc (GSK)? Insider Monkey
Mar-26-19 07:45PM  Better Buy: Eli Lilly vs. GlaxoSmithKline Motley Fool
Mar-22-19 07:00AM  FOCUS-UPS eyes in-home health services with U.S. vaccine project Reuters
01:00AM  FOCUS-UPS eyes in-home health services with U.S. vaccine project Reuters
Mar-20-19 11:24AM  Emergent Begins Phase III Study on Anthrax Vaccine AV7909 Zacks
10:43AM  Glaxo Presents Encouraging Data on Endometrial Cancer Drug Zacks
Mar-19-19 03:00PM  Post-GSK purchase, Tesaro readies for cancer clash with Merck American City Business Journals
02:19PM  GSK reports positive data from trial of endometrial cancer drug Reuters
Mar-18-19 03:53PM  Novartis' (NVS) Alcon Acquired PowerVision for $285 Million Zacks
Mar-15-19 01:37PM  UK shares up after vote for Brexit delay; oil majors gain Reuters
Mar-14-19 03:12PM  5 Undervalued Stocks to Invest In InvestorPlace
Mar-12-19 05:45PM  GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know Zacks
09:14AM  Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now? Zacks
07:31AM  How the UK Makes Money Investopedia
Mar-08-19 03:46PM  Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks
01:24PM  Top Research Reports for Microsoft, Mastercard & General Electric Zacks
Mar-07-19 02:45PM  Why the Triangle is ranked among the top 5 life science hubs in the U.S. American City Business Journals
01:50PM  Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks
01:45AM  [$$] Monthly jab for HIV treatment passes late-stage trials Financial Times
Mar-06-19 02:55PM  Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA Zacks
Mar-05-19 08:42AM  Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda Zacks
Mar-04-19 08:15AM  New Research: Key Drivers of Growth for GlaxoSmithKline plc, nVent Electric, Dana, FMC, Qualys, and Affiliated Managers Group Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-01-19 02:37PM  3 Life Sciences Stocks to Invest In InvestorPlace
Feb-27-19 03:30PM  Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 Zacks
12:48PM  Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates Zacks
12:40PM  Versum Sticks With Merger Plan as German Merck Barges In Bloomberg
11:49AM  Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down Zacks
10:47AM  Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
10:14AM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4 Zacks
09:38AM  Top Ranked Income Stocks to Buy for February 27th Zacks
08:12AM  Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover Zacks
08:06AM  MarketPulse: Mylan Bleeds After Q4 Results, Guidance Fall Short
07:15AM  AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study Zacks
Feb-26-19 10:47AM  Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor Zacks
10:29AM  Top Ranked Income Stocks to Buy for February 26th Zacks
09:39AM  The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto Zacks
07:16AM  Better Buy: GlaxoSmithKline vs. Eli Lilly Motley Fool
Feb-25-19 10:27AM  Novartis In-Licenses Rights to Heart Candidate From Ionis Zacks
07:00AM  [$$] SFO appoints Sarah Lawson QC as new general counsel Financial Times
Feb-22-19 04:58PM  [$$] U.K. Closes Corruption Probes of GlaxoSmithKline, Rolls-Royce Individuals The Wall Street Journal
12:18PM  British fraud office abandons Rolls-Royce, GSK investigations Reuters
11:48AM  British fraud office abandons Rolls-Royce, GSK investigations Reuters
11:26AM  Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates Zacks
08:52AM  Top Ranked Income Stocks to Buy for February 22nd Zacks
07:27AM  UK's Serious Fraud Office drops probes at Rolls Royce, GSK Reuters
06:34AM  [$$] SFO ends investigations into Rolls-Royce and GSK Financial Times
05:00AM  [$$] SFO abandons cases as new chief tackles backlog Financial Times
Feb-21-19 03:34PM  Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y Zacks
10:08AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
Feb-20-19 09:53AM  Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct Zacks
Feb-19-19 04:14PM  [$$] Drug Maker Pernix Therapeutics Files for Bankruptcy, Blaming Competition From Generics The Wall Street Journal
09:14AM  Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo Zacks
09:04AM  New Strong Buy Stocks for February 19th Zacks
Feb-15-19 04:27PM  Innoviva, Inc. -- Moody's announces completion of a periodic review of ratings of Innoviva, Inc. Moody's
09:02AM  Top Ranked Growth Stocks to Buy for February 15th Zacks
Feb-14-19 03:44PM  Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B Zacks
02:02PM  Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up Zacks
08:58AM  AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales Zacks
08:14AM  Top Ranked Income Stocks to Buy for February 14th Zacks
07:13AM  New Strong Buy Stocks for February 14th Zacks
Feb-13-19 03:29AM  Edited Transcript of GSK.L earnings conference call or presentation 6-Feb-19 2:00pm GMT Thomson Reuters StreetEvents
Feb-12-19 11:01AM  Mylan launches Advair generic at one-third price Reuters
10:41AM  Mylan launches Advair generic at one-third price Reuters
09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Sensodyne, parodontax, Poligrip, Voltaren, Panadol, Otrivin, and Theraflu brand names. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, pods, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, and malted drinks and foods. Its primary collaboration is with 23andMe; and strategic alliance is with Merck KGaA to jointly develop and commercialize M7824. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLCFormer 10% holderJul 30Buy11.00148,8181,636,998624,422Aug 01 06:32 PM
GLAXOSMITHKLINE PLC10% OwnerJul 17Buy12.5080,0001,000,0001,934,006Jul 17 05:01 PM
GLAXOSMITHKLINE PLC10% OwnerJul 02Buy13.00269,2303,499,9903,697,912Jul 03 05:59 PM